Evidence method
Level · gp.fundamentals.capex_revenue_ratio
7.77% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Mar 31, 2023
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-017250General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-157.12% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-2.52% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
52.79% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
50.38% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-151.92% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
86.60% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
38.97% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 8.82%
- Current
- 7.77%
- Delta
- -1.06%
- Previous
- -99.26%
- Current
- -157.12%
- Delta
- -57.86%
- Previous
- 20.06%
- Current
- -2.52%
- Delta
- -22.58%
- Previous
- 7.80%
- Current
- 52.79%
- Delta
- 44.99%
- Previous
- 68.75%
- Current
- 50.38%
- Delta
- -18.37%
- Previous
- -108.03%
- Current
- -151.92%
- Delta
- -43.89%
- Previous
- 76.50%
- Current
- 86.60%
- Delta
- 10.10%
- Previous
- 29.94%
- Current
- 38.97%
- Delta
- 9.03%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT CAPEX_INTENSITY_DECREASED →Transitioned To · ADPT CASH_GENERATION_DECREASED →Transitioned To · ADPT GROWTH_DECREASED →Transitioned To · ADPT INVENTORY_PRESSURE_INCREASED →Transitioned To · ADPT MARGIN_DECREASED →Transitioned To · ADPT PROFITABILITY_DECREASED →Transitioned To · ADPT R_AND_D_INTENSITY_INCREASED →Transitioned To · ADPT SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.